This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
New Strong Buy Stocks for January 26th
by Zacks Equity Research
FYBR, SPPJY, KMTUY, PRTG and ASML have been added to the Zacks Rank #1 (Strong Buy) List on January 26, 2023.
Best Momentum Stocks to Buy for January 20th
by Zacks Equity Research
NBSE, PRTG and NOMD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 20, 2022.
New Strong Buy Stocks for January 20th
by Zacks Equity Research
NBSE, PRTG, RELL, HOWL and PATH have been added to the Zacks Rank #1 (Strong Buy) List on January 20, 2022.
How Much Upside is Left in Portage Biotech Inc. (PRTG)? Wall Street Analysts Think 160%
by Zacks Equity Research
The consensus price target hints at a 159.8% upside potential for Portage Biotech Inc. (PRTG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
New Strong Buy Stocks for November 1st
by Zacks Equity Research
FFNW, PTEN, PRTG, NTNX and GAMB have been added to the Zacks Rank #1 (Strong Buy) List on November 1, 2022.
Bears are Losing Control Over Portage Biotech Inc. (PRTG), Here's Why It's a 'Buy' Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Portage Biotech Inc. (PRTG), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
How Much Upside is Left in Portage Biotech Inc. (PRTG)? Wall Street Analysts Think 268%
by Zacks Equity Research
The consensus price target hints at a 268.4% upside potential for Portage Biotech Inc. (PRTG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Does Portage Biotech Inc. (PRTG) Have the Potential to Rally 206% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Portage Biotech Inc. (PRTG) points to a 206.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.